Impact of baseline characteristics on extensive-stage SCLC patients treated with etoposide/carboplatin: A secondary analysis of a phase III study.

Published in: The clinical respiratory journal (2018)

Number of metastatic sites is the most important predictive factor for overall and PFS among patients with extensive-stage SCLC treated with systemic chemotherapy within a clinical trial.

Keyphrases

phase iii
clinical trial
open label
phase ii
double blind
squamous cell carcinoma
small cell lung cancer
placebo controlled
locally advanced
study protocol